Quidelortho Corporation · NASDAQ:QDEL

Quidelortho — William Blair 46th Annual Growth Stock Conference 2026

24 slides from Quidelortho's conference presentation, Jun 2, 2026

  1. Slide 1: William Blair 46th Annual Growth Stock Conference

    June 2, 2026 William Blair 46th Annual Growth Stock Conference Brian J. Blaser President & Chief Executive Officer © 2026 QuidelOrtho Corporation. All rights reserved. | 1

  2. Slide 2: Forward-Looking Statements and Non-GAAP Financial Measures

    Forward-Looking Statements and Non-GAAP Financial Measures Forward-Looking Statements: This presentation of QuidelOrtho Corporation ("QuidelOrtho" or the "Company") contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are

  3. Slide 3: Well Positioned to Take Advantage of Trends Driving Increased Diagnostics Testing

    Well Positioned to Take Advantage of Trends Driving Increased Diagnostics Testing Global aging Decentralization Growth in emerging Increased focus on population and of healthcare markets from health awareness, burden of chronic increased longevity and disease investment preventive care William Blair

  4. Slide 4: A Diversified Pureplay IVD Leader With Durable Growth

    A Diversified Pureplay IVD Leader With Durable Growth Advancing the power of diagnostics for a healthier future for all Across key Highly Across healthcare recurring regions settings revenue Molecular 1% Instruments 4% Labs DS 2% North Latin America 9% 55% America 55% JPAC 11% IH 20% Recurring $2.7B

  5. Slide 5: Highly Differentiated in Key IVD Market Segments

    Highly Differentiated in Key IVD Market Segments Labs Immunohematology Point of Care & Molecular 55% FY25 Revenue 20% FY25 Revenue 1 23% FY25 Revenue  Innovative dry-slide chemistry technology  Global market leader in  A market leader in U.S. respiratory  A market leader in acute care and immuno

  6. Slide 6: Broad Global Product Portfolio

    Broad Global Product Portfolio Labs VITROS 5600 and VITROS 450 Chemistry System VITROS ECL Systems VITROS XT 7600 Systems  Expands addressable  Integrated systems offer  First new VITROS platform market and increases 5 * Global scalable and reliable since 2019, the successor opportunity for OUS #

  7. Slide 7: Broad Global Product Portfolio

    Broad Global Product Portfolio NULEXA Diagnostics QUIDEL TRIAGE SOFIA Platform Point  Rapid, automated Platform System  A market leader in  Ultra-fast molecular results of Care & and LIS connected with reliable and in ~6-10 minutes, at an cardiac, including the accessible cost for POC only POC CL

  8. Slide 8: Introducing QuidelOrtho's Newest Molecular System – LEX is now NULEXA

    Introducing QuidelOrtho’s Newest Molecular System – LEX is now NULEXA Multiplex ultra-rapid † RT-PCR CLIA waived Results in approximately 6-10 minutes † RT-PCR: Reverse transcription-polymerase chain reaction William Blair 46th Annual Growth Stock Conference | June 2, 2026 © 2026 © 2026 QuidelOrtho

  9. Slide 9: Four Simple Steps to Results

    Four Simple Steps to Results Seamless, sample-to-answer multiplex PCR results 1 2 3 4 Swab one Break off the swab in Select “New Test” and Early-read function nostril for the cartridge and close. place closed cartridge provides real-time 15 seconds. into the instrument, results. Full test results th

  10. Slide 10: Highly Attractive and Differentiated Molecular Platform

    Highly Attractive and Differentiated Molecular Platform 1 Competitor #1 Market leader Competitor #2 Traditional molecular NULEXA PCR With Best-in-class Speed Assays Flu A+B / Strep RSV CLIA waived CLIA waived CLIA waived    SARS A Panel  Room temperature (Reagent storage) Refrigeration (Reagent

  11. Slide 11: Innovation Driving the Next Phase of Growth

    Innovation Driving the Next Phase of Growth Focused investments designed to increase customer value, expand market access and accelerate recurring revenue growth 2026 - 2030+ non-exhaustive pipeline Today 2026 2027 - 2030+ Current Instruments VITROS 450 Next-Gen Enterprise Solutions 40+ New Assays V

  12. Slide 12: Multiple Initiatives for Fueling Long-term Growth

    Multiple Initiatives for Fueling Growth Long-term Growth Strategic Levers partnerships license agreements Anchored by QO’s M&A strategic pillars Cost Delivering an exceptional structure Customer improvement Experience New products/ Prioritizing innovation  Access new revenue streams  Expand into n

  13. Slide 13: Executive Leadership Team

    Executive Leadership Team Brian Blaser Joseph Busky Lee Bowman President & Chief Financial Officer Chief Human Resources Officer Chief Executive Officer Phil McLellan Nathaniel Sisitsky, Jonathan Siegrist, Chief Operations Officer Esq. Ph.D. Chief Legal Officer Executive Vice President of R&D & Chie

  14. Slide 14: FY25 Financial Results and FY26 Guidance

    FY25 Financial Results and FY26 Guidance FY25 Total Revenue Financial guidance4 (as of 5/5/26) FY 2026 $2.73B Total revenues (reported) $2.70 – $2.75B 5% y/y 1 Adjusted EBITDA $615 – $630M FY25 Adjusted Adjusted EBITDA margin 23% EBITDA Adjusted diluted EPS $1.80 – $2.00 $597M Free Cash Flow $100 –

  15. Slide 15: Free Cash Flow Generation

    Free Cash Flow Generation Cash flow expected to gain momentum in 2H 2026 $187M Growth (mid-point of FY26 guidance) Target 50% Recurring FCF- $110 Adj. EBITDA Conversion in 2H’27 Drivers:  Significantly lower 1x cash use  AR improvements  Decreased inventory $(77)  Decreased CapEx $(112)  Workin

  16. Slide 16: Capital Allocation Priorities

    Capital Allocation Priorities Cash flow Profitability debt leverage  Commercial focus on  Companywide focus on highest growth, increasing free cash flow, profitable markets including management incentives tied to  Cost-savings initiatives Enterprise achievement for direct procurement and facility

  17. Slide 17: Unlocking Value

    Unlocking Value A diagnostics leader with global scale in highly attractive and growing markets Adjusted ~$50B TAM EBITDA margin Highly differentiated solutions creating Target market segments expansion lifetime customer value growing MSD+ +240 bps FY25 Mid- to high-20%s target Focus on growth, prof

  18. Slide 18: Thank you

    Thank you @® QuidelOrtho”

  19. Slide 19: Appendix

    Appendix © 2026 QuidelOrtho Corporation. All rights reserved. | 19

  20. Slide 20: Non-GAAP Adjustments

    Non-GAAP Adjustments Fiscal Year In millions FY 2025 FY 2024 Incremental depreciation on PP&E fair value adjustment $ 12.6 $ 20.8 Amortization of deferred cloud computing implementation costs 2.8 0.4 Accelerated depreciation 3.8 — Other adjustments 0.2 0.1 Cost of sales, excluding amortization of in

  21. Slide 21: FY Non-GAAP Reconciliation

    FY Non-GAAP Reconciliation Fiscal Year 2025 Fiscal Year 2024 In millions GAAP Adjustments (a) Non-GAAP GAAP Adjustments (a) Non-GAAP Gross profit $ 1,274.2 $ 19.4 $ 1,293.6 $ 1,286.5 $ 21.3 $ 1,307.8 Selling, marketing and administrative 746.3 (36.8) 709.5 766.8 (37.1) 729.7 Research and development

  22. Slide 22: Non-GAAP Reconciliations – Adjusted EBITDA

    Non-GAAP Reconciliations – Adjusted EBITDA Fiscal Year In millions FY 2025 FY 2024 Net loss $ (1,131.8) $ (2,052.0) Depreciation and amortization 442.0 453.4 Interest expense, net 177.6 163.5 Provision for (benefit from) income taxes 24.1 (79.5) Restructuring, integration and other charges 263.6 127

  23. Slide 23: Non-GAAP Reconciliations

    Non-GAAP Reconciliations Fiscal Year In millions FY 2025 FY 2024 Net cash provided by operating activities $105.2 $83.0 Less: Acquisitions of property, plant, equipment, investments, and 188.2 195.1 intangibles Proceeds from government assistance allocated to fixed assets (6.5) - Free Cash Flow $(76

  24. Slide 24: quidelortho.com

    ae SAMMI quidelortho.co

QuidelOrtho — William Blair 46th Annual Growth Stock Conference 2026 on 6ix